Comparison of Quality of Life before and after pancreaticoduodenectomy
A prospective study
Keywords:
Pancreatic neoplasms, Pancreaticoduodenectomy, Quality of lifeAbstract
Background: Pancreatic cancer is an aggressive malignancy, and surgical resection is the only therapeutic option with pancreaticoduodenectomy being considered the standard of care. It is essential to take into account the patients’ Quality of Life after the resection, in order to make more informed decisions about treatment options. Objective: The aim of the study was to determine perceived Quality of Life levels among patients who undergo pancreaticoduodenectomy, in a period of six months after surgery. Methods: This prospective study was conducted on all patients (n=40) who underwent pancreaticoduodenectomy in Attikon University General Hospital in Athens, Greece, from January 2013 to June 2015. The Quality of Life was assessed by use of EORTC QLQ-C30 and EORTC QOL-PAN26 questionnaires at four phases: First, after admission at the hospital preoperatively, and then one month, three months, and six months postoperatively. Repeated measurements analysis of variance (ANOVA) was used in order to evaluate changes in Quality of Life measures during the follow-up (postoperative) period. Data analysis was conducted using SPSS version 19. A p-value of less than or equal to 0.05 was set as the level of significance. Results: The study revealed a mixed image. Except for the nausea and vomiting scale, where indeed a symptom increase is initially reported and then gradually decreases below preoperative levels by 6 months, scoring in many symptom scales worsens postoperatively. From first to fourth assessment, fatigue (Mean from 23.61 to 38.72, p=0.005) and financial difficulties scoring (Mean from 5.98 to 42.42, p<0.001) consistently worsen. Functionality scales scoring also tends to get worse between first and fourth assessment, with statistically significant changes for physical (p<0.001), role (p<0.001) and social functioning (p<0.001). However, a slight improvement can be noted in many scales from third to fourth assessment, as in diarrhea (Mean from 32.38 to 29.29), pancreatic pain (Mean from 17.71 to 2.34), global health status (Mean from 50.48 to 52.53) and social functioning (Mean from 43.81 to 48.48) scales. Conclusions: Quality of Life levels among patients who undergo pancreaticoduodenectomy are getting worse following surgery. However, the longitudinal study of these changes may improve patients’ postoperative life by formulating evidence-based interventions concerning symptoms treatment and psychological and social support.
References
Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: A comprehensive review and update. Dis Mon.
; 59(11): 368-402. doi: 10.1016/j.disamonth.2013.08.001. PMID: 24183261.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359- 86. doi: 10.1002/ijc.29210. PMID: 25220842.
Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, et al. Global Trends in Pancreatic
Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol. 2016;
(10): 1452-62. doi: 10.1016/j.cgh.2016.05.034. PMID: 27266982, PMCID: PMC5028258.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer
incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United
States. Cancer Res. 2014; 74(11): 2913-21. doi: 10.1158/0008-5472.CAN-14-0155. PMID: 24840647.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11–30. doi:
3322/caac.21166. PMID: 23335087.
Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer:
symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005; 7(5): 189-97.
PMID: 15960930.
Weledji EP, Enoworock G, Mokake M, Sinju M. How Grim is Pancreatic Cancer? Oncol Rev. 2016; 10(1):
doi: 10.4081/oncol.2016.294. PMID: 27471581.
Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in
pancreatic cancer. CA Cancer J Clin. 2013; 63(5): 318-48. doi: 10.3322/caac.21190. PMID: 23856911.
Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, et al. A Systematic Review of the
Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J
Gastrointest Cancer. 2015; 46(3): 201-11. doi: 10.1007/s12029-015-9724-1. PMID: 25972062.
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most
important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004; 91(5):
-94. doi: 10.1002/bjs.4484. PMID: 15122610.
Muniraj T, Barve P. Laparoscopic staging and surgical treatment of pancreatic cancer. N Am J Med Sci.
; 5(1): 1-9. doi: 10.4103/1947-2714.106183. PMID: 23378948.
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev
Clin Oncol. 2010; 7(3): 163–72. doi: 10.1038/nrclinonc.2009.236. PMID: 20101258.
Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ, et al. Meta-analysis of radical
resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015; 102(12): 1459–72. doi:
1002/bjs.9892. PMID: 26350029.
Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and
management. World J Gastroenterol. 2014; 20(31): 10740–51. doi: 10.3748/wjg.v20.i31.10740. PMID:
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced
pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17(6): 801-10.
doi: 10.1016/S1470-2045(16)00172-8. PMID: 27160474.
Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, et al. Is there a role for surgical resection
in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol.
; 42(10)1533-9. doi: 10.1016/j.ejso.2016.06.398. PMID: 27423449.
Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced
pancreatic cancer. Cochrane Database Syst Rev. 2014; (2): CD010244. doi:
1002/14651858.CD010244.pub2. PMID: 24578248.
Marmor S, Burke EE, Virnig BA, Jensen EH, Tuttle TM. A comparative analysis of survival outcomes
between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
Cancer. 2016; 122(21): 3378-85. doi: 10.1002/cncr.30199. PMID: 27419382.
Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older
adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015; 121(5): 758-65. doi:
1002/cncr.29119. PMID: 25369293.
Arthur AE, Delk A, Demark-Wahnefried W, Christein JD, Contreras C, Posey JA, et al. Pancreatic cancer
survivors' preferences, barriers, and facilitators related to physical activity and diet interventions. J Cancer
Surviv. 2016; 10(6): 981-89. doi: 10.1007/s11764-016-0544-5. PMID: 27138993.
Gerritsen A, Jacobs M, Henselmans I, van Hattum J, Efficace F, Creemers GJ, et al. Developing a core set
of patient-reported outcomes in pancreatic cancer: A Delphi survey. Eur J Cancer. 2016; 57: 68-77. doi:
1016/j.ejca.2016.01.001. PMID: 26886181.
Cooper C, Burden ST, Molassiotis A. An explorative study of the views and experiences of food and
weight loss in patients with operable pancreatic cancer perioperatively and following surgical intervention.
Support Care Cancer. 2015; 23(4): 1025-33. doi: 10.1007/s00520-014-2455-1. PMID: 25277960.
Gooden HM, White KJ. Pancreatic cancer and supportive care – pancreatic exocrine insufficiency
negatively impacts on quality of life. Support Care Cancer. 2013; 21(7): 1835-41. doi: 10.1007/s00520- 013-1729-3. PMID: 23397095.
Eshuis WJ, de Bree K, Sprangers MA, Bennink RJ, van Gulik TM, Busch OR. Gastric emptying and
quality of life after pancreatoduodenectomy with retrocolic or antecolic gastroenteric anastomosis. Br J
Surg. 2015; 102(9): 1123-32. doi: 10.1002/bjs.9812. PMID: 26086157.
Chen KT, Devarajan K, Hoffman JP. Morbidity among long-term survivors after pancreatoduodenectomy
for pancreatic adenocarcinoma. Ann Surg Oncol. 2015; 22(4): 1185-9. doi: 10.1245/s10434-014-3969-y.
PMID: 25384699.
Eaton AA, Gonen M, Karanicolas P, Jarnagin WR, D'Angelica MI, DeMatteo R, et al. Health-Related
Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Ann Surg Oncol.
; 23(7): 2137-45. doi: 10.1245/s10434-015-5077-z. PMID: 26786091.
Heerkens HD, Tseng DS, Lips IM, van Santvoort HC, Vriens MR, Hagendoorn J, et al. Health-related
quality of life after pancreatic resection for malignancy. Br J Surg. 2016; 103(3): 257-66. doi:
1002/bjs.10032. PMID: 26785646.
Richter S, Uslar V, Tabriz N, Mueser T, Weyhe D. Progressive postresection program (pPRP) after
pancreatic resection: study protocol for a randomized controlled trial. Trials. 2016; 17: 74. doi:
1186/s13063-016-1200-0. PMID: 26863867.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization
for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international
clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5): 365-76. PMID: 8433390.
Kontodimopoulos N, Ntinoulis K, Niakas D. Validity of the Greek EORTC QLQ-C30 and QLQ-BR23 for
measuring health-related quality of life in breast cancer patients. Eur J Cancer Care (Engl). 2011; 20(3):
-61. doi: 10.1111/j.1365-2354.2009.01170.x. PMID: 20345453.
Mystakidou K, Tsilika E, Parpa E, Kalaidopoulou O, Smyrniotis V, Vlahos L. The EORTC core quality of
life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: Validity
and reliability in a Hellenic sample. Int J Cancer. 2001; 94(1): 135-39. PMID: 11668488.
Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, et al. Development of a disease
specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL
questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer. 1999; 35(6): 939-41. PMID:
Arvaniti M, Danias N, Theodosopoulou E, Smyrniotis V, Karaoglou M, Sarafis P. Quality of Life Variables
Assessment, Before and After Pancreatoduodenectomy (PD): Prospective Study. Glob J Health Sci. 2015;
(6): 203-10. doi: 10.5539/gjhs.v8n6p203. PMID: 26755486.
Riediger H, Adam U, Fischer E, Keck T, Pfeffer F, Hopt UT, et al. Long-term outcome after resection for
chronic pancreatitis in 224 patients. J Gastrointest Surg. 2007; 11(8): 949-59. doi: 10.1007/s11605-007- 0155-6. PMID: 17534689.
Karanicolas PJ, Davies E, Kunz R, Briel M, Koka HP, Payne DM, et al. The pylorus: take it or leave it?
Systematic review and meta-analysis of pylorus-preserving versus standard whipple
pancreaticoduodenectomy for pancreatic or periampullary cancer. Ann Surg Oncol. 2007; 14(6): 1825-34.
doi: 10.1245/s10434-006-9330-3. PMID: 17342566.
Fragulidis GP, Arkadopoulos N, Vassiliou I, Marinis A, Theodosopoulos T, Stafyla V, et al. Pancreatic
leakage after pancreaticoduodenectomy: the impact of the isolated jejunal loop length and anastomotic
technique of the pancreatic stump. Pancreas. 2009; 38(7): e177-82. doi: 10.1097/MPA.0b013e3181b57705.
PMID: 19730152.
Shaw CM, O'Hanlon DM, McEntee GP. Long-term quality of life following pancreaticoduodenectomy.
Hepatogastroenterology. 2005; 52(63): 927–32. PMID: 15966234.
Fitzmaurice C, Seiler CM, Büchler MW, Diener MK. Survival, mortality and quality of life after pylorus- preserving or classical Whipple operation. A systematic review with meta-analysis. Chirurg. 2010; 81(5):
-71. doi: 10.1007/s00104-009-1829-2. PMID: 20020091.
Kostro J, Sledziński Z. Quality of life after surgical treatment of pancreatic cancer. Acta Chir Belg. 2008;
: 679–84. PMID: 19241917.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
